Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2026)

Bicycle Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $40.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 543.63% year-over-year to $40.1 million; the trailing twelve-month figure through Mar 2026 stood at $40.1 million (up 543.63% YoY), and the FY2025 full-year result was $17.0 million, up 4.47% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $40.1 million, up from $17.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $44.4 million in Q3 2025, with the low at $2.7 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $15.9 million across 5 years, with a median of $13.0 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 844.27% — and 2024, when it plunged 78.01%.
• Bicycle Therapeutics' Accumulated Expenses stood at $26.5 million in 2022, then sank by 49.36% to $13.4 million in 2023, then advanced by 21.49% to $16.3 million in 2024, then rose by 4.47% to $17.0 million in 2025, then soared by 136.02% to $40.1 million in 2026.
• The last three Accumulated Expenses figures came in at $40.1 million (Q1 2026), $17.0 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.